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Abstract
Background: Studies from our laboratory and others have shown that cysteine-rich 61 (Cyr61) may be involved in tumor
proliferation and invasion. In earlier studies, we demonstrated increased insulin-like growth factor-I (IGF-1) is associated with
breast tumor formation and poor clinical outcomes. In our current study we have investigated IGF-1 regulation of Cyr61 and
whether targeting IGF-1 could inhibit Cyr61 induced tumor growth and proliferation.
Methods: Several ATCC derived normal and breast cancer cell lines were used in this study: MDA-MB231, BT474, MCF-7, and
SKBR3. We also tested cells stably transfected in our laboratory with active Akt1 (pAkt; SKBR3/AA and MCF-7/AA) and
dominant negative Akt1 (SKBR3/DN and MCF-7/DN). In addition, we used MCF-7 cells transfected with full length Cyr61
(CYA). Monolayer cultures treated with IGF-1 were analyzed for Cyr61 expression by RT-PCR and immunohistochemical
staining. Migration assays and MTT based proliferation assays were used to determine invasive characteristics in response to
IGF-1/Cyr61 activation.
Results: Cells with activated Akt have increased levels of Cyr61. Conversely, cells with inactive Akt have decreased levels of
Cyr61. IGF-1 treatment increased Cyr61 expression significantly and cells with high level of Cyr61 demonstrate increased
invasiveness and proliferation. Cyr61 overexpression and activation led to decrease in E-cadherin and decrease in FOXO1.
Inhibition of the PI3K and MAPK pathways resulted in significant decrease in invasiveness and proliferation, most notably in
the PI3K pathway inhibited cells.
Conclusion: The findings of this study show that IGF-1 upregulates Cyr61 primarily through activation of the Akt-PI3K
pathway. IGF-1 induced MAPK plays a partial role. Increase in Cyr61 leads to increase in breast cancer cell growth and
invasion. Hence, targeting Cyr61 and associated pathways may offer an opportunity to inhibit IGF-1 mediated Cyr61
induced breast cancer growth and invasion.
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Introduction
Breast cancer mortality is due in large part to metastasis of the
tumor to distant sites. Particularly, metastasis to the bone is the
most common location and results in decreased patient survival
[1]. Identifying biomarkers in patients at high risk of breast cancer
metastasis have important therapeutic and translational implica-
tions. The CCN family of proteins have been implicated in bone
metastasis in recent studies. Cyr61 is the first member of the CCN
family of proteins which is named after the three proteins in the
family (Cyr61, CTGF, NOV) [2]. The more recent classification
of CCN family includes: CCN1 (Cyr61), CCN2 (CTGF), CCN3
(Nov), CCN4 (WISP-1), CCN5 (WISP-2), and CCN6 (WISP-3).
The CCN proteins are highly upregulated during wound healing
and studies have shown that the CCN family also plays a role in
tumor invasion and metastasis. Upregulation of the CCN proteins
can also induce expression of a variety of angiogenic and
lymphogenic factors such as the vascular endothelial growth
factors [3].
The CCN family proteins share homologous binding/regulato-
ry domains that give each protein their distinct place in the family
[3]. The members of the CCN family typically have four
conserved functional domains which include an insulin-like growth
factor binding protein-like module (IGFBP), a von Willebrand
factor type C repeat module (VWC), a thrombospondin type-1
repeat module (TSP-1), and a cysteine-knot containing module
(CT). Investigations on the specific functionalities of the CCN
family domains have been limited, especially on the IGFBP
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domain, however some reports do highlight that specific domains
may play more key roles in invasiveness [4]. Importantly, it is
known that the IGFBP domain on CCN1 shares homology with
the traditional insulin-like growth factor 1 (IGF-1) binding proteins
[3].
IGF-1 is an important modulator of cell growth, differentiation,
and invasiveness [5]; thus interactions between IGF-1 and CCN1
are of significant interest. The majority of IGF-1 is found in
circulation; however, in vitro studies have clearly shown that many
major tissue systems including epithelial, reproductive, and
cardiovascular tissues express IGF-1 and the IGF-1 receptor
(IGF-1R) [6]. The bioavailability of IGF-1 is regulated by a variety
of IGF binding proteins (IGFBPs). The roles of specific IGFBPs
are still under investigation; however the most commonly accepted
mode of action is by increasing the half-life of IGF-1 and affecting
IGF-1 binding to the IGF-1R as a free ligand. Binding of IGF-1
with IGF-1R, a tyrosine kinase receptor, results in a series of
intracellular signaling cascades which, in epithelial cells such as
found in breast, colon, and prostate tissue, result in activation of
the PI3K/Akt and MAPK pathways. The PI3K/Akt and MAPK
pathways are master cell regulatory centers and subsequently
promote cell proliferation, growth, and survival [7,8].
IGF-1 has clearly been shown to be a potent mitogen in both in
vitro and in vivo studies capable of breast cell tumorogenesis and
breast cancer cell progression [7,9,10]. Evidence from clinical
evaluation of systemic IGF-1 levels also reveals that IGF-1 plays a
central role in breast cancer risk and outcome. Previous studies
from our group and others identified that women with increased
serum or plasma IGF-1 levels had increased risk for breast cancer.
Patients with increased IGF-1 had poor overall survival and
disease-free survival [11–14].Conversely, patients with positive
prognosis of drug-response to therapy such as Tamoxifen
concurrently exhibited reduced IGF-1 levels [11,15]. Given the
breadth of evidence implicating IGF-1 in neoplasia, several
preclinical and clinical attempts have been made to develop
target therapies towards IGF-1 Receptors and downstream
effectors such as PI3K/Akt. Although several have reached even
the Phase III clinical trial phase, results are not satisfactory and
conclusive targets and therapies remain to be identified [16].
Given the known associations between Cyr61 and invasion,
IGF-1 and breast cancer, and the potential interactions through
the IGFBP domain on Cyr61, we investigated the role of IGF-1 on
Cyr61 induced cell growth and invasion. Our earlier studies
demonstrated that IGF-1 increases the risk for breast cancer and
contributes to poor outcome in cancer patients [11] and pAkt is
associated with poor clinical outcome in breast cancer patients
[17]. Hence, we wanted to investigate if the Cyr61 levels played a
role in pAkt overexpressing breast cancer cells, and to elucidate
mechanisms associated with the IGF-1 axis and Cyr61 induced
cell invasion. We further examined if the MAPK pathway, another
key IGF-1 mediated signaling cascade, played a role in IGF-1
mediated Cyr61 expression and subsequent proliferation and
invasion.
Methods
Cell Culture
The cell lines MCF-7, MDA-MB231, NIH-3T3 and SKBR3
cells were obtained from American Type Tissue Culture (ATCC).
Cells were maintained in a T25 tissue culture flask in DMEM 50/
50 16media containing 10% Fetal Bovine Serum, supplemented
with L-glutamine and Penicillin/Streptomycin at 37uC tempera-
ture [FBS (Invitrogen), L-glutamine (Invitrogen), 10 units/mL
Penicillin G and 10 mg/mL streptomycin (Invitrogen)]. Addition-
ally, altered Akt expressing subclones were utilized. SKBR3 and
MCF-7 cells were stably transfected in the Vadgama Laboratory
[18] with either constitutively active Akt (SKBR3/AA and MCF-
7/AA) or inactive dominant negative Akt (SKBR3/DN or MCF-
7/DN). The AA and DN subclones of SKBR3 and MCF-7 cells
were maintained in the same growth media as the Wildtype cells,
with an addition of 0.5 g/ml geneticin (GIBCO) to the culture
media. MCF-7 cells stably transfected with full-length Cyr61
(MCF-7 CYA). The MCF-7 CYA clone was obtained as part of
collaboration with the Koeffler Lab (Cedars/UCLA). Detailed
methods on the Cyr61 transfectants have been described
previously in publications from the Koeffler Lab [4,19]. The
MCF-7 cell line transfected with only the Vector (MCF-7 CMV)
showed identical properties as the wild type MCF-7 cells.
RNA isolation and Reverse Transcriptase Real Time PCR
When cells reached a confluence of 90%, the cells were
collected and RNA was extracted using TRIzol reagent (Invitro-
gen) according to manufacturer’s instructions. The cDNA was
synthesized by reverse transcription (RT) with ThermoScript RT-
PCR system (Invitrogen) according to the manufacturer’s instruc-
tions. Real time-PCR analysis was performed with iCycle iQ real-
time PCR detection system (Bio-Rad Lab, Hercules, CA) using
SYBR Green Master Mix (#204143, QIAGEN). The primers
used were as follows: Cyr61,59-ACTTCATGGTCCCAGT-
GCTC-39(forward) and 59-AATCCGGGTTTCTTTCACA-39
(reverse);18 s, 59-GATCCATTGGAGGGCAAGTC-39(forward)
and 59-TCCCAAGATCCAACTACGAG-39 (reverse); E-cad-
herin, 59- (ATGGGGGCTTCATTCACAT-39)(forward) and 59-
(TTTGAGGCCAAGCAGCAG)-39(reverse); FOXO1, 59- (TTT-
GGACTGCTTCTCTCAGTTCCTGC)-39(forward) and 59-(TT-
TGACAATGTGTTGCCCAACCAAAG)-39(reverse).
Growth Factor and Inhibitor Induction Treatments
To determine whether IGF-1 up regulates Cyr61, MCF-7 cells
were induced with IGF-1 (100 ng/ml) for 20 minutes, 4 hours,
and 24 hours. Cyr61 mRNA levels were measured at different
time intervals. Experimental cells were plated in 60 mm culture.
Once cells reached 70% confluence they were switched to serum
free media with 0.1% BSA for overnight starvation. Upon
exposure to IGF-1 for the designated time the cells were spun
down for RNA extraction. LY294002 (50 mM) and PD98059
(30 mM), which are PI3K and MAPK inhibitors, respectively, were
used in order to determine their specific roles in response to IGF-1
mediated Cyr61 upregulation. All conditions that had a combi-
nation of IGF-1 and a kinase inhibitor were pretreated with the
specific inhibitor 1 hour before the addition of IGF-1. The IGF-1
induced changes in Cyr61, E-Cadherin, and FOXO1 levels were
assessed using RT-PCR and IF analysis.
Migration Assay
Transwell plates (24-well), with cell culture inserts of 6.5 mm in
diameter and 8.0-mm pore size, were used during the Migration
Assay. The mouse fibroblast line, NIH3T3, was seeded on the
bottom of the wells of the Transwell apparatus (25,000 cells/well).
The cells were allowed to grow for two days in the normal culture
media, and placed in serum-free medium (DMEM + 0.1 BSA) one
day prior to the insertion of the Transwell inserts. Prior to plating
onto the Transwells, breast tumor cells were disassociated into
single cells and suspended in serum-free medium. Subsequently,
the cells were plated on the top wells of the Transwell inserts at a
density of 25,000/well (or ml) (200 mL/well). Treatments includ-
ing 100 ng/mL of IGF-1, 50 mM LY294002, 30 mM PD98059
and combination of treatments, were added and the cells were
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allowed to migrate for 40 hours. The migratory cells on the
bottom of the membrane were fixed with 5% Glutaraldehyde
(Sigma) for 10 minutes at room temperature, and were then
stained with 5% Toludine Blue (Sigma) and 2% NaCO3 (Fisher
Scientific) for 15 minutes at room temperature. Excess staining
was removed with water, and the chambers were air-dried.
Pictures were taken under the microscope and cells numbers were
quantified counting the number of migrated cells compared to the
total number of cells.
Immunofluorescence
Cells were plated for immunofluorescence (IF) onto 24 well
plate circular glass inserts and fixed upon reaching 70%
confluence. Fixation was performed by incubating cells with 4%
Paraformaldehyde for 10 minutes followed by a two minute
fixation with ice cold pure methanol. The cells were blocked with
2% horse serum diluted in 16 PBS for 1 hour, then incubated
with the primary CYR61 antibody (Santa Cruz Biotechnology,
Rabbit pAB 1:400 dilution) for 1 hour. The cells were washed 3
times with 16 PBS for 5 minutes each. The cells were then
incubated with secondary FITC fluorescence antibody (Santa
Cruz Biotechnology, 1:500) for one hour. Subsequently, the cells
were washed 3 times with 16 PBS for 5 minutes each time, and
mounted with VECTASHIELD Mounting Media with DAPI
(Vector Laboratories). The cells were then imaged; FITC
representing the Cyr61 protein is green, and DAPI representing
the nuclear counterstain is blue.
MTT Proliferation Assay
In order to assess growth responses of the different cells to the
different treatments, MTT proliferation assays were performed. A
total of 5,000 cells were plated per well in 96 well plates and
allowed to attach. Cells were serum starved overnight before the
addition of treatments: 100 ng/mL of IGF-1, 50 mM LY294002,
30 mM PD98059 and combination of the three treatments for
24 hrs and 48 hrs. After the treatments for the appropriate
durations of time, 50 uL of MTT reagent (3-(4, 5-dimethylthia-
zolyl-2)-2, 5-diphenyltetrazolium bromide) was added to each well
and incubated for 4 hours at 37uC. The MTT reagent was
removed and DMSO was added to each well. Results were
immediately read on a microplate reader (Promega GloMax
Microplate Reader) at the 560 nm absorbance wavelength. All
assays were performed in n= 6, and the data are presented as the
mean 6 SD.
Statistical Analysis
Statistical analysis was performed using SPSS Software (version
17. IBM, Chicago, USA). Comparisons were made with the
Student’s t test and the two-tailed P-value statistic was considered.
Comparisons were statistically significant if P,0.05. The com-
parisons from which each P-value was obtained are annotated in
the figure legends.
Results
Cyr61 expression in different breast cancer cell types
Baseline/constitutive levels of Cyr61 were assessed in four
breast cancer cell lines each representing a specific breast cancer
subtype (Figure 1A). These cell lines were obtained from
American Type Culture Collection (ATCC). MCF-7 is an ER/
PR+ and HER2- breast cancer cell line which forms localized
tumors with very low invasiveness. As can be expected, MCF-7 has
very low Cyr61 mRNA levels (Figure 1A). SKBR3 (HER2+) and
BT474 (ER+/PR+/HER2+) are both HER2+ breast cancer cell
lines which have some invasive properties and both express higher
levels of Cyr61 than MCF-7. MDAMB231 is a triple negative
receptor breast cancer cell line which is highly invasive, and has
the highest levels of Cyr61 mRNA (Figure 1A). The P-value is ,
0.01 for all comparisons relative to MCF-7 WT. This study chose
to focus on MCF-7 breast cancer cells since it was the least invasive
line with constitutively low levels of Cyr61, and which expresses
significant levels of IGF-1 receptors.
IGF-1 regulates Cyr61 expression
The effect of IGF-1 treatment was investigated in relation to
Cyr61 expression at different time-points (Figure 1B–D). Cells
were induced with 100 ng/ml of IGF-1 for 0 minutes, 20 minutes,
4 hours, and 24 hours. In MCF-7 WT Cells (Figure 1B), IGF-1
induction resulted in a significant increase of Cyr61 expression,
particularly at the 20 minute time point (P,0.001). We subse-
quently investigated whether the Cyr61 upregulation due to IGF-1
was mediated through the PI3K/Akt pathway which is one of the
central pathways in IGF-1 induced cancer growth. MCF-7 clones
transfected with either AA (constitutively active Akt) or DN
(constitutively dominant-negative) Akt were induced with 100 ng/
ml of IGF-1 (Figure 1C and 1D, respectively). Inactivation of the
Akt pathway (such as in the MCF-7 DN cells) resulted in a
significant decrease by 45% in Cyr61 levels in response to IGF-1
compared to the MCF-7 WT cells (Figure 1D). In the MCF-7 AA
clone with constitutively high Akt activation, IGF-1 mediated
increase of Cyr61 was not as significant as the MCF-7 WT,
especially at 20 minutes (P,0.01 vs. P,0.001, respectively). This
data suggests these cells may already have high Cyr61 and not
respond as sensitively to IGF-1. These data demonstrate that IGF-
1 induction results in Cyr61 expression. In addition, Akt activation
is a significant contributor to Cyr61 expression; however, there
also may be other pathways activated by IGF-1, such as MAPK
that may also play a role. It should be noted that Cyr61 levels
stabilized after 4 hours, which may suggest there may be a
feedback loop that lowers the levels of Cyr61.
Cyr61 expression is increased in breast cancer cells with
activated Akt
The baseline levels of Cyr61 expression in MCF-7 WT, MCF-7
AA and MCF-7 DN were assessed to confirm that Akt activation
or loss alone can regulate Cyr61 expression (Figure 1E). As
shown in Figure 1E, the baseline levels of Cyr61 were
significantly higher in the MCF-7 AA cells compared to the
MCF-7 WT cells confirming that Akt activation alone results in
Cyr61 expression (P,0.001). Furthermore, Cyr61 levels were the
lowest in the MCF-7 DN cells. These trends were successfully
confirmed in a second cell line, SKBR3 (Figure 1F), with P,
0.001 for comparisons of SKBR3 AA and SKBR3 DN with the
SKBR3 WT. In sum, these data suggest that Akt activation
(phosphorylation) is strongly associated with Cyr61 expression.
The mechanisms whereby Akt activation results in Cyr61
expression are not clearly known, however, downstream tran-
scription factors regulated by Akt may play a role as shown later in
the data.
Cyr61 overexpression results in increased cell invasion
In order to investigate the effects of IGF-1 and its mediated
pathways on Cyr61 expression, proliferation, and invasion in
breast cancer, a cell model system was utilized which includes
MCF-7 WT and a MCF-7 Cyr61 transfectant clone. The Koeffler
lab provided the MCF-7 clone which has overexpressing full
length Cyr61 (MCF-7 CYA, [19]). The MCF-7 CYA was utilized
IGF-1 Regulates Cyr61 in Breast Cancer
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to confirm that Cyr61 overexpression alone can contribute to
breast cancer cell proliferation and invasion in a non-invasive
parental cell line (MCF-7). The effects of IGF-1 stimulation, and
the signaling transduction pathways activated in these cells have
not been investigated to date. The data in Figure 2A confirms
that MCF-7 cells transfected with Cyr61 showed significantly
increased levels of Cyr61 mRNA (P,0.001). This increase in
mRNA was correlated with increase in Cyr61 protein expression,
as confirmed from immunofluorescent analysis (Figure 2B).
Consequently, Cyr61 overexpressing cells showed increased cell
invasion (Figure 2C–D), P,0.05.
IGF-1 induces cell proliferation and invasion via Cyr61
expression – Role of the PI3K/Akt Pathway
Next, we examined the effects of IGF-1 treatment on breast
cancer cell proliferation, invasion, and Cyr61 expression in
relation to the PI3K/Akt pathway (Figure 3A–C). In MCF-7
WT cells, treatment of IGF-1 resulted in significant Cyr61
expression increase (P,0.001), however, blocking the PI3K/Akt
pathway with LY294002 reduced Cyr61 expression significantly
(P,0.01) consistent with the previous data (Figure 3A). Treat-
ment of IGF-1 and LY294002 together resulted in a reduction of
IGF-1 induced Cyr61 expression in MCF-7 WT (Figure 3A). The
constitutive levels of Cyr61 mRNA in MCF-7 CYA were high.
Since MCF-7 CYA is transfected with Cyr61, this is to be
expected.
Both MCF-7 WT and MCF-7 CYA showed increase in cell
proliferation (Figure 3B) upon IGF-1 treatment (P,0.001
compared with untreated in both cell lines). Treatment with
LY294002 resulted in a significant decrease in proliferation in all
cell types (70% in MCF-7 WT, 48% in MCF-7 CYA), confirming
that PI3K/Akt plays a role. Treatment with IGF-1 in the presence
of LY294002 was not sufficient to stimulate cell proliferation
indicating IGF-1 mediated proliferation is significantly regulated
through PI3K/Akt (P,0.001).
Migration in response to IGF-1 treatment and LY294002
inhibition was also investigated (Figure 3C). IGF-1 treatment
induced significant increase (.10 fold) in MCF-7 WT cell
migration (P,0.001). MCF-7CYA which express high levels of
constitutive Cyr61 did not demonstrate as much of an additional
increase in cell migration upon IGF-1 treatment (P,0.05). This
implies that cells with constitutively increased Cyr61 levels are
already invasive; however, they are not completely independent of
further influence from IGF-1-mediated invasion.
Figure 1. Cyr61 Levels in Various Breast Cancer Cell Lines – Baseline and in Response to IGF-1. (A) Baseline mRNA expression of Cyr61 in
Wildtype MCF-7, SKBR3, BT474, and MDAMB231 as determined by RT-Q-PCR. (B–D) Cyr61 expression after IGF-1 treatment at baseline, 20 minutes,
4 hours, and 24 hours in (B) MCF-7 WT, (C) MCF-7 DN, and (D) MCF-7 AA cells. Cyr61 is increased by treatment of IGF-1, especially at 20 minutes. (E)
Expression of Cyr61 mRNA in MCF-7 WT cells compared to MCF-7 AA (transfectant with constitutively active Akt), and MCF-7 DN (transfectant with
dominant negative constitutively inactive Akt). (F) The results obtained in the MCF-7 cell line were confirmed by a second breast cancer cell line,
SKBR3. All mRNA levels were adjusted for the housekeeping gene, 18S. P-values were calculated relative to MCF-7 WT in (A,E), to 0 Minutes in (B–D),
and SKBR3 WT in (F). P,0.05 is statistically significant.
doi:10.1371/journal.pone.0103534.g001
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IGF-1 induces cell proliferation and invasion via Cyr61
expression – Role of the MAPK Pathway
Cyr61 levels in MCF-7 WT cells which were concurrently
treated with IGF-1 and LY294002, did not demonstrate a
complete loss of Cyr61 expression when the PI3K/Akt pathway
was blocked. In addition, inhibition with LY294002 did not
completely inhibit IGF-1 induced cell proliferation. This data
suggested that perhaps an additional pathway may be involved in
IGF-1 mediated Cyr61 expression and its effect on cell prolifer-
ation and invasion. We examined the contribution of the MAPK
pathway since it is one of the central pathways activated by IGF-1
(Figure 4A–C). Figure 4A shows that inhibition of the MAPK
pathway with the MAPK inhibitor, PD98059, also results in a
significant decrease in IGF-1 mediated Cyr61 expression (P,
0.001). Again the effect was not seen as significantly (P,0.01) in
the constitutively high Cyr61 expressing cells, MCF-7 CYA. In the
proliferation response, interestingly, MAPK inhibition alone did
not result in a significant decrease in proliferation in MCF-7 WT
(Figure 4B). However, PD98059 did prevent IGF-1 mediated
proliferation (P,0.01) in both cell lines.
In MCF-7 CYA cells (Figure 4B), PD98059 treatment alone
did result in a significant decrease in proliferation similar to that
observed in the LY294002 blocked MCF-7 CYA cells from
Figure 3B. These data suggest that cells which overexpress Cyr61
(MCF-7 CYA) are dependent on both the PI3K/Akt pathway and
MAPK pathway for proliferation. However, blocking MAPK in
the presence of IGF-1 stimulation was not sufficient to attenuate
proliferation to the extent as observed by blocking with LY294002
(comparing Figure 3B right panel vs. Figure 4B right panel) –
P,0.001. These data suggest that inhibition of the MAPK
pathway attenuates, but does not significantly diminish IGF-1
mediated proliferation as inhibition of PI3K/Akt.
When assessing migration in cells treated with PD98059 alone,
there was no change in the migration of cells in the MCF-7 WT
(Figure 4C). However, in Cyr61 overexpressing cells, MCF-7
CYA, inhibition of the MAPK pathway by PD98059 resulted in a
significant decrease in cell migration (P,0.001).
Figure 2. Confirmation of Cyr61 levels and Invasiveness in MCF-7 WT and MCF-7 CYA. (A) The mRNA expression of Cyr61 was assessed by
RT-Q-PCR and (B) by immunofluorescent staining (FITC - green – Cyr61; DAPI – blue – nuclei). (C) Quantification of invasiveness from invasion
chamber. (D) Red arrows demonstrate positive examples from invasion chamber. CYA cells are 9 times more invasive than the MCF-7 WT cells. All
mRNA levels were adjusted for the housekeeping gene, 18S. P-values were calculated relative to MCF-7 and P,0.05 is statistically significant.
doi:10.1371/journal.pone.0103534.g002
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IGF-1 induction increases Cyr61 and decreases E-cadherin
and FOXO1 expression
Increase in Cyr61 expression upon IGF-1 treatment resulted in
increased cell invasion properties. Hence, we examined E-
cadherin expression which is a key protein in cell adhesion. E-
cadherin levels were assessed in MCF-7 WT (low Cyr61, non-
invasive) and MDAMB231 (high Cyr61, highly invasive) cell lines
in response to IGF-1 treatment. Both cell lines had a significant
decrease (P,0.001) in E-cadherin in response to IGF-1 treatment
(Figure 5A–B). Cyr61 was fairly high in these cells treated with
IGF-1 (Figure 5A–B left panels); fifteen fold in MCF-7 and two
fold in MDAMB231 (which is expected since this cell line already
Figure 3. Effects of IGF-1 and LY294002 Induction on Proliferation, Invasion, and Cyr61 Expression in MCF-7 WT and CYA. (A) The
mRNA expression of Cyr61 was assessed by RT-Q-PCR. All mRNA levels were adjusted for the housekeeping gene, 18S. (B) Results from proliferation
assay after 48 hour IGF-1 (100 ng/mL) and LY294002 (50 mM) treatment in MCF-7 WT and MCF-7 CYA. Each condition was plated into 6 identical wells
in a 96 well plate. All treatments were standardized relative to the untreated condition for each cell line. (C) Results from Invasion assay after 40 hour
IGF-1 (100 ng/mL) and LY294002 (50 mM) treatment in MCF-7 WT and MCF-7 CYA. P-values were assessed relative to the untreated condition in each
assay, with P,0.05 considered statistically significant.
doi:10.1371/journal.pone.0103534.g003
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has very high constitutive Cyr61 levels) – P,0.001. These data
indicate that upon Cyr61 increase, which is a biomarker for
invasion, there is a concurrent decrease in a key cell adhesion
protein, E-cadherin.
Recent studies from our laboratory [18,20] have shown that loss
or down regulation of FOXO1 is associated with aggressive cancer
cell phenotype and poor prognosis in cancer patients. Further-
more, FOXO1 is a downstream target of the PI3K/Akt pathway,
which we have identified affects Cyr61 expression and prolifera-
Figure 4. Effects of IGF-1 and PD98059 Induction on Proliferation, Invasion, and Cyr61 Expression in MCF-7 WT and MCF-7 CYA. (A)
The mRNA expression of Cyr61 was assessed by RT-Q-PCR. All mRNA levels were adjusted for the housekeeping gene, 18S. (B) Proliferation assay
summary data after 48 hour IGF-1 (100 ng/mL) and PD98059 (30 mM) treatment in MCF-7 WT and MCF-7 CYA. Each condition was plated into 6
identical wells in a 96 well plate. All treatments were standardized relative to the untreated condition for each cell line. (C) Results from Invasion assay
after 40 hour IGF-1 (100 ng/mL) and PD98059 (30 mM) treatment in MCF-7 WT and MCF-7 CYA. P-values were assessed relative to the untreated
condition in each assay, with P,0.05 considered statistically significant.
doi:10.1371/journal.pone.0103534.g004
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tion. Hence, we examined if IGF-1 treatment caused deregulation
of FOXO1 in association with increase in Cyr16. Figure 5A–B
(right panel) demonstrates that increased Cyr61 levels in response
to IGF-1 resulted in decrease in FOXO1. Both MCF-7 and
MDAMB231 showed a significant decrease in FOXO1 levels -
over 60% in MCF-7 (P,0.01) and over 80% in MDAMB231 (P,
0.001). These data indicate two potential mechanisms whereby
IGF-1 induced proliferation and invasions may occur – deregu-
lation of FOXO1 and loss of E-cadherin. Additional research is
needed to investigate the mechanisms linking FOXO1 and E-
cadherin with Cyr61.
Discussion
Identification of biomarkers which play a clear functional role in
breast cancer etiology and invasion will be key for improving
breast cancer outcomes. Notably, these biomarkers have the
potential, with additional validation, to one day possibly inform
therapeutic options for breast cancer patients. Breast cancer
metastasis to the bone is a common metastatic event associated
with reduced survival. Bisphosphonates have been shown to
prevent bone metastasis and reduce tumor burden in several
preclinical [21] and clinical models [22]. Extracellular matrix
proteins related to invasion in tumors, such as the CCN family
which are responsive to well-established growth factor signaling
implicated in cancer, are strong candidates for molecular
examination. The CCN family of proteins play a role in so many
key molecular processes [2]. They are defined by their various
homologous domains – including the IGF Binding Protein domain
which is of particular interest given that previous studies in our lab
and others have identified that IGF-1 serum levels are associated
with breast cancer tumorogenesis and progression [11,12]. In
addition, studies have also shown that patients with elevated
expression of CCN1 in their breast cancer have a worse prognosis
[19,23]. Hence, these pathways and interplay of the IGF-1 axis
with the CCN1 expression is of particular interest and has
important translational potential.
In the present study, the effect of IGF-1 induction on Cyr61
activity and subsequent cell proliferation and invasion was
examined. The study identified that IGF-1 induced an increase
in Cyr61 levels in MCF-7 WT cells which resulted in both
increased proliferation and invasion. This was confirmed by the
transfection of Cyr61 full-length protein into MCF-7 (MCF-7
CYA) which also resulted in significant increase in proliferation
and invasion as compared with WT. Previous studies by Xie et al
[19,23], and Tsai et al [24] confirm that increased Cyr61 in breast
cancer cells result in aggressive properties. Together, our studies
indicate that Cyr61 is inducible both by estrogen as well as IGF-1,
rendering this molecule highly sensitive to growth factor induction.
Physiologically, patients with high IGF-1 circulatory levels have
been shown to have reduced survival from breast cancer; hence,
the upregulation of Cyr61 which mediates cell migration may
result in increased metastasis observed.
Figure 5. Inverse Relationship between IGF-1 induced Cyr61 upregulation and decreased E-cadherin and FOXO1 expression is
confirmed in two cell lines. The mRNA expression of Cyr61, E-cadherin, and FOXO1 were assessed by RT-Q-PCR. All mRNA levels were adjusted for
the housekeeping gene, 18S. (A) Expression of Cyr61, E-cadherin, and FOXO1 in response to IGF-1 induction (100 ng/mL) following serum starvation
in MCF-7 WT cells; and (B) MDAMB231 cells. P-values were assessed relative to the untreated condition within each cell line, and P,0.05 considered
statistically significant.
doi:10.1371/journal.pone.0103534.g005
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The mechanism whereby IGF-1 stimulates Cyr61 was also
investigated in the present study. The PI3K/Akt pathway was
assessed given that it is one of the central downstream pathways
from IGF-1 and previous studies from our group and others
identified a central role of PI3K/Akt in breast cancer outcomes
[17]. Transfection of constitutively active Akt resulted in
significant increase in Cyr61 expression, whereas inactive Akt
transfection resulted in a decrease. This was further confirmed by
inducing the Akt pathway with IGF-1 and blocking the Akt
pathway with LY294002. The cell proliferative activity and
invasion mirrored Cyr61 transcriptional levels. However, the
IGF-1 induced transcription of Cyr61 was not completely
abolished. Therefore, MAPK the other key downstream pathway
from IGF-1 was assessed. Inhibition of MAPK resulted in a
significant decrease in Cyr61 expression in the WT cells which was
not restored by IGF-1 induction, unlike the response seen by
blocking the PI3K/Akt pathway. However, similarly to the
LY294002 response, blocking MAPK with PD98059 reduced
proliferation and invasion. Together these data suggest that IGF-1
mediated Cyr61 expression, proliferation, and invasion are
intrinsically but not exclusively mediated through MAPK and
PI3K/Akt signaling with high Cyr61 expressing cells less sensitive
to MAPK inhibition than PI3K/Akt inhibition in presence of IGF-
1.
Furthermore, we posit it is the activation of Akt (pAkt) rather
than the expression of Akt that is the driver of proliferation and
invasion in our model. When the PI3K inhibitor is applied, we see
loss of the growth and proliferation because phosphorylation of
Akt is inhibited, rather than the actual expression. In preliminary
evaluation of the cell lines, we identified that baseline levels of
pAkt were higher in MCF-7 CYA cells than MCF-7 WT cells
(data not shown). These data are consistent with our previous
findings indicating that aggressive breast cancer phenotypes do not
necessarily have increased levels of Akt, but do have increased
levels of active Akt (pAkt) [17]. This finding was further confirmed
in breast cancer patient clinical samples; patient tissues with high
pAkt levels had reduced disease free survival [17].
Previous studies have highlighted the role of estrogen-induced
Cyr61 expression in breast cancer [19,25]. However, the presence
of the estrogen receptor (ER) is implied to be present in these cell
lines. Paradoxically, Cyr61 is most highly expressed in ER- cells
lines such as MDA-MB231 as reported previously [19,26] and
confirmed in this present study. The finding from our study
implicating IGF-1 in Cyr61 expression and subsequent prolifer-
ation and invasion can shed light on this paradox as well as present
several translational implications. As indicated earlier, IGF-1 levels
have been associated with more aggressive breast cancers resulting
in reduced disease free survival and reduced response to breast
cancer treatment [11]. Furthermore, IGF-1 levels are higher
among African-American women [11,27,28] and triple negative
breast cancer is more frequent among African-American women
[29]. Therefore, it is possible that increased IGF-1 induced Cyr61
activity among these cohorts through classical PI3K/Akt and
MAPK signaling is a mechanism whereby these tumors progress to
a more aggressive and invasive phenotype. These data were
preliminarily confirmed by our study which identified the
corresponding reduction of E-cadherin expression in response to
IGF-1 induction and Cyr61 expression. E-cadherin is a well-
established ‘‘gate-keeper’’ for cell-adhesion and loss has been
associated with epithelial mesenchymal transition and increased
invasiveness [30–32]. Loss of E-cadherin in response to Cyr61 has
been shown in Cyr61 induction studies in gastric cancer [33],
however, we are among the first to report these findings in breast
cancer.
Furthermore, the high IGF-1 and Cyr61 levels may play a role
in therapy and drug-resistance. There is data to support this for
patients with high IGF-1 levels [11,15]. In vitro studies by
Menendez et al demonstrated Cyr61 overexpression resulted in
Taxol resistance [26] which was further confirmed by Lai and
colleagues [34]. These data add an additional layer of complexity
related to lack of therapeutic response and progression of the
tumor to metastasis in Cyr61 overexpressing cells. Previously,
studies from our group identified the forkhead-family member,
FOXO1, to play a role in drug-resistance and survival in breast
cancer [18,20]. Our present study presents preliminary data that
Figure 6. Proposed Schematic of IGF-1 mediated signaling in relation to Cyr61 expression and activity.
doi:10.1371/journal.pone.0103534.g006
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FOXO1 was downregulated in response to IGF-1 induction and
associated with Cyr61 expression. Hence, Cyr61 expression may
be a key molecule, mediated through IGF-1, which contributes to
drug resistance and the aggressive breast cancer phenotype.
Additional studies are needed to confirm these findings. Early
phase clinical trials have already attempted to directly target IGF
signaling through anti-IGF receptor (IGF1R) antibodies with
limited success [16]. Hence, targeting Cyr61 directly or through
one of the downstream signals may offer alternative therapeutic
options.
Direct Cyr61 targeting has been attempted recently by several
groups. Lin and colleagues have just developed a mAb termed
093G9 which targets the VWC domain of the Cyr61 and reduces
MDA-MB-231 cell proliferation, migration, and invasion [35].
Similarly, Jim Leu et al recently developed a mAb termed YM1B
targeting the DM region of Cyr61 which has successfully
attenuated cell migration/invasion through the integrin/Rac1/
ERK signaling axis [36]. These are undergoing additional
validation and not yet have reached clinical testing. Therapies
targeting the Cyr61 binding partners such as integrins may offer
additional strategies. Cyr61 has been shown to bind with integrins
such as avb5 and a3b5, in the extracellular matrix space [37].
Integrin binding has been shown to induce actin filament
rearrangement which can contribute to morphological changes-
such as epithelial-mesenchymal transition [33]. Menendez and
colleagues have demonstrated in several studies that targeting the
ab integrins in Cyr61 overexpressing breast cells successfully
restores drug-response [26,38]. This may be another therapeutic
target to investigate further for attenuating Cyr61 mediated cell
activity and drug resistance.
In summary, this study demonstrates that IGF-1, which is
significantly involved in poor prognosis and outcome in women
with breast cancer, upregulates Cyr61 through both the MAPK
and PI3K/Akt pathways resulting in cell invasion and growth
(Figure 6). Furthermore, IGF-1 mediated cell invasion and growth
are accompanied by the loss of E-cadherin and FOXO1, key
biomarkers regulating EMT/cell-adhesion and drug response,
respectively. Thus, one of the possible mechanisms whereby high
levels of IGF-1 among patients may result in poor outcome and
prognosis may be due to the activation of Cyr61 and downreg-
ulation of the other protective biomarkers. Since IGF-1 is a growth
factor essential for maintaining systemic homeostasis in key tissues
such as the muscles and heart, targeting of IGF-1 may not be
feasible for attenuating cancer risk and/or progression. Thus,
targeting downstream players, such as Cyr61 may be more
realistic potential therapeutic objectives for invasive breast cancer
cells.
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